D. Waterkamp

发表

Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR).

Keunchil Park, J. Mazières, J. Vansteenkiste, 2015 .

14LBA Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR)

J. Yi, J. Mazières, J. Vansteenkiste, 2015 .

Isolation of targeted AAV2 vectors from novel virus display libraries

J. Kleinschmidt, O. Müller, M. Trepel, 2006, The journal of gene medicine.

Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials.

J. Tabernero, F. Kabbinavar, H. Hurwitz, 2013, The oncologist.

Atezolizumab (atezo) plus platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): Update from a phase Ib study.

G. Giaccone, F. Hodi, S. Gettinger, 2017 .

Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.

T. Gruenberger, J. Bridgewater, M. Rivoire, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies

C. Gridelli, F. de Marinis, Manali I. Patel, 2017, PloS one.

Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs. docetaxel in 2L/3L NSCLC (POPLAR)

Keunchil Park, J. Yi, J. Mazières, 2016, Pneumologie.

Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC

D. Gandara, F. Ciardiello, C. Barrios, 2016 .

Clinical trials of MPDL3280A (anti-PDL1) in patients (pts) with non-small cell lung cancer (NSCLC).

S. Gettinger, C. Chappey, F. Kabbinavar, 2014 .

PL04a.02: OAK, a Randomized Ph III Study of Atezolizumab vs Docetaxel in Patients with Advanced NSCLC: Results from Subgroup Analyses

Keunchil Park, D. Gandara, F. Ciardiello, 2017 .

Recovery of ionic liquids from wastewater: Aggregation control for intensified membrane filtration

J. F. Fernández, J. Thöming, D. Waterkamp, 2008 .

Abstract 2651: Clinical activity and immune correlates from a phase Ib study evaluating atezolizumab (anti-PDL1) in combination with FOLFOX and bevacizumab (anti-VEGF) in metastatic colorectal carcinoma

P. Hegde, H. Hurwitz, J. Bendell, 2016 .

On the Effect of Enhanced Mass Transfer on Side Reactions in Capillary Microreactors during High‐Temperature Synthesis of an Ionic Liquid

J. Thöming, D. Waterkamp, Matthias Engelbert, 2009 .

Phase Ib evaluation of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) in patients (pts) with metastatic renal cell carcinoma (mRCC).

Suzanne F. Jones, M. Sznol, J. Bendell, 2015 .

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Carlos Barrios, Toyoaki Hida, Keunchil Park, 2017, The Lancet.

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Keunchil Park, J. Yi, J. Mazières, 2016, The Lancet.

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

Suzanne F. Jones, Fabien Gaire, P. Hegde, 2016, Nature Communications.

Synthesis of ionic liquids in micro-reactors—a process intensification study

Michael Schlüter, Jorg Thöming, Michael Heiland, 2007 .

Bevacizumab (bev) in combination with capecitabine (cape) for the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC): Results of a randomized international phase III trial (AVEX).

D. Shin, D. Cunningham, I. Láng, 2013 .

Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC).

S. Adams, L. Molinero, J. Diamond, 2016 .

Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer.

G. Giaccone, F. Hodi, S. Gettinger, 2018, European journal of cancer.

Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.

D. Shin, D. Cunningham, I. Láng, 2013, The Lancet. Oncology.

Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC).

H. Hurwitz, J. Bendell, M. Pishvaian, 2015 .

OA20.01 Tumor Mutation Burden (TMB) is Associated with Improved Efficacy of Atezolizumab in 1L and 2L+ NSCLC Patients

G. Hampton, P. Hegde, G. Frampton, 2017 .

Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC

David S. Shames, Matthew D. Hellmann, Garrett M. Frampton, 2016 .

Non-classical response measured by immune-modified RECIST and post-progression treatment effects of atezolizumab in 2L/3L NSCLC: Results from the randomized phase II study POPLAR.

Keunchil Park, J. Yi, J. Mazières, 2016 .

Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).

G. Giaccone, F. Hodi, S. Gettinger, 2015 .

Efficacy, safety and predictive biomarker results from OAK, a randomized phase III study comparing atezolizumab with docetaxel in patients with advanced NSCLC

F. Ciardiello, F. Barlesi, M. Ballinger, 2017, Pneumologie.

Abstract P2-11-06: Safety and clinical activity of atezolizumab (anti-PDL1) in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer

S. Adams, L. Molinero, J. Diamond, 2016 .

1049OSAFETY AND EFFICACY OF MPDL3280A (ANTI-PDL1) IN COMBINATION WITH BEVACIZUMAB (BEV) AND/OR CHEMOTHERAPY (CHEMO) IN PATIENTS (PTS) WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS.

H. Hurwitz, J. Bendell, M. Pishvaian, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

A Phase III study of atezolizumab with carboplatin plus etoposide in patients with extensive-stage small cell lung cancer (IMpower133)

G. Giaccone, T. Mok, Xiongwen Tang, 2016 .

513 Safety, activity and biomarkers of atezolizumab (MPDL3280A) with platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): A Phase Ib study

G. Giaccone, F. Hodi, S. Gettinger, 2015 .

CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

N. Segal, M. Rodriguez-Ruiz, M. Das Thakur, 2024, Nature communications.